摘要
阿尔茨海默病(Alzheimer’s disease,AD)是最常见的神经退行性疾病之一,严重损害患者的记忆和认知能力。研究者经过多年探索仍无法找到治愈AD的有效药物。源于间充质干细胞(mesenchymal stem cells,MSCs)旁分泌的生长因子、细胞因子、趋化因子等生物因子及外泌体具有抗炎、清除β-淀粉样蛋白(β-amyloid peptide,Aβ)、促进神经生长以及抑制细胞凋亡等作用,MSCs的旁分泌作用被认为是治疗AD最有前途的临床疗法之一。该文首先总结了AD的发病机制,然后根据MSCs所具有的特征和优势,综述了利用MSCs的旁分泌作用治疗AD的临床前研究,期望为将来临床上治疗AD提供有价值的信息。
AD (Alzheimer’s disease),one of common neurodegenerative diseases,severely impairs the memory and cognitive ability of patients.There are no effective drugs to cure AD,though researchers have explored for years.Paracrine growth factors,cytokines,chemokines and exosomes produced by MSCs (mesenchymal stem cells) possess the capabilities of anti-inflammatory,Aβ (β-amyloid peptide) clearance,promotion of synaptic remodeling,and antioxidant effects.They are considered to be one of the most promising clinical therapies for AD.This article firstly summarizes the pathogenesis of AD,and then reviews the preclinical studies of paracrine effect of MSC on the treatment of AD based on the characteristics and advantages of MSCs and exosomes.This review will provide valuable information for clinical treatment of AD in future.
作者
冯培培
陈宇
陈语湛
韩舒宁
蒋悦
冯佳婷
鲁承皓
候瑞霞
竺亚斌
FENG Peipei;CHEN Yu;CHEN Yuzhan;HAN Shuning;JIANG Yue;FENG Jiating;LU Chenghao;HOU Ruixia;ZHU Yabin(Medical School of Ningbo University,Ningbo 315211,China;Affiliated Hospital of Medical School of Ningbo University,Ningbo 315040,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2020年第8期1428-1436,共9页
Chinese Journal of Cell Biology
基金
浙江省自然科学基金(批准号:LY20C100001)
宁波市科技创新2025重大专项(批准号:2018B10052)
宁波市自然科学基金(批准号:2019A610199)资助的课题。
